◀ Back to AR

AR — CCND1

Pathways - manually collected, often from reviews:

• NCI Pathway Database Coregulation of Androgen receptor activity: T-DHT/AR/CyclinD1 complex (AR-CCND1) → Cyclin D1 (CCND1) (modification, collaborate) Knudsen et al., Cancer Res 1999*, Burd et al., Mol Endocrinol 2005*
  Evidence: mutant phenotype, physical interaction
• NCI Pathway Database Coregulation of Androgen receptor activity: T-DHT/AR/CyclinD1 complex (AR-CCND1) → AR/T-DHT complex (AR) (modification, collaborate) Knudsen et al., Cancer Res 1999*, Burd et al., Mol Endocrinol 2005*
  Evidence: mutant phenotype, physical interaction
• NCI Pathway Database Coregulation of Androgen receptor activity: Cyclin D1 (CCND1) → AR/T-DHT complex (AR) (modification, collaborate) Knudsen et al., Cancer Res 1999*, Burd et al., Mol Endocrinol 2005*
  Evidence: mutant phenotype, physical interaction
• NCI Pathway Database Coregulation of Androgen receptor activity: T-DHT/AR/CyclinD1 complex (AR-CCND1) → T-DHT/AR/CDK6 complex (AR-CDK6) (transcription, inhibits)
  Knudsen et al., Cancer Res 1999*, Lim et al., Proc Natl Acad Sci U S A 2005*
  Evidence: mutant phenotype, reporter gene
• NCI Pathway Database Coregulation of Androgen receptor activity: T-DHT/AR/CyclinD1 complex (AR-CCND1) → PSA (KLK3) (transcription, inhibits) Knudsen et al., Cancer Res 1999*, Lim et al., Proc Natl Acad Sci U S A 2005*
  Evidence: mutant phenotype, reporter gene

Protein-Protein interactions - manually collected from original source literature:

Studies that report less than 10 interactions are marked with *

• ARGDB interaction: AR — CCND1 (regulation) Gregory et al., J Androl 2001*
• IRef Biogrid Interaction: CCND1 — AR (physical association, affinity chromatography technology) Petre-Draviam et al., Oncogene 2005*
• IRef Biogrid Interaction: CCND1 — AR (direct interaction, pull down) Petre-Draviam et al., Oncogene 2005*
• IRef Biogrid Interaction: CCND1 — AR (physical association, affinity chromatography technology) Knudsen et al., Cancer Res 1999*
• IRef Dip Interaction: AR — CCND1 (physical association, coimmunoprecipitation) Knudsen et al., Cancer Res 1999*
• IRef Hprd Interaction: AR — CCND1 (in vivo) Knudsen et al., Cancer Res 1999*, Petre-Draviam et al., Oncogene 2005*
• IRef Hprd Interaction: AR — CCND1 (in vitro) Knudsen et al., Cancer Res 1999*, Petre-Draviam et al., Oncogene 2005*
• IRef Ophid Interaction: AR — CCND1 (aggregation, interologs mapping) Brown et al., Bioinformatics 2005
• IRef Ophid Interaction: AR — CCND1 (aggregation, confirmational text mining) Knudsen et al., Cancer Res 1999*

Text-mined interactions from Literome

Burd et al., Proc Natl Acad Sci U S A 2006 (Prostatic Neoplasms) : In the prostate, cyclin D1a acts through discrete mechanisms to negatively regulate androgen receptor (AR) activity and thus limit androgen dependent proliferation
Mullany et al., Am J Physiol Gastrointest Liver Physiol 2010 : Previous reports have shown that cyclin D1 can directly enhance estrogen receptor activity and inhibit androgen receptor activity in a ligand independent manner and thus may play an important role in hormone-responsive malignancies